Briefly, tumor cells in AITL/FHTCL demonstrated a very characteristic immunophenotypic signature with positive expressions of CD2, CD4, CD5, CD45, and heterogeneous CD7 but negative expressions of surface CD3, CD8, CD16, CD56, CD25, CD26, and CD30. This evidence concerns the gene CD4 and neoplasm.